Industry gets first view of FDA reform legislation
This article was originally published in Clinica
Executive Summary
The US medical device industry gave a less than warm reception to the latest House FDA reform legislation as representatives took their first look last week. Their initial reaction: Nancy Kassebaum's senate bill is better. For one thing, the Kansas Republican specifies a 180-day review clock; the House version does not, reports Clinica's Washington correspondent, Duffy Miller.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.